MRI in Inflammatory Myopathies and Autoimmune-Mediated Myositis

  • Umesh A. Badrising
  • Hermien E. Kan
  • Jan JGM Verschuuren
Part of the Medical Radiology book series (MEDRAD)


In this chapter, dermatomyositis, polymyositis, inclusion body myositis, and the necrotizing myopathies are discussed in detail with regard to their clinical features, laboratory and histopathological findings, mimics and the imaging findings with magnetic resonance imaging, computed tomography, and ultrasound. With the focus on magnetic resonance imaging, its discriminating role between disorders during the diagnostic work-up, the evaluation of the extent and activity of the disease, and the gathering of information on fat replacement of muscles are considered. Furthermore, its use to locate the best site for a muscle biopsy to enhance the diagnostic yield of a histopathologically confirmed diagnosis and its use during the follow-up of patients in assessing the therapeutic effect of immunosuppressive and immunomodulating therapies and to detect signs of relapse are outlined.


Muscle Biopsy Spinal Muscular Atrophy Fatty Infiltration Serum Creatine Kinase Inclusion Body Myositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Adenosine triphosphate


Creatine kinase


Computed tomography




Diffusion weighted imaging




Human immunodeficiency virus


Human T cell lymphotropic virus


3-hydroxy-3-methylglutaryl-coenzyme A reductase


Inclusion body myositis


Idiopathic inflammatory myopathies


Juvenile dermatomyositis


Membrane attack complex


Melanoma differentiation matrix protein


Major histocompatibility complex


Magnetic resonance imaging


Magnetic resonance spectroscopy


Myositis specific antibody


Muscle unit action potential


Necrotizing myopathy


Nuclear matrix protein




Positron emission tomography


Inorganic phosphate




Single recognition particle


Short tau inversion recovery



The authors would like to thank Janneke van de Vlekkert for her contribution.


  1. Adams EM, Chow CK, Premkumar A, Plotz PH (1995) The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 15(3):563–574PubMedCrossRefGoogle Scholar
  2. Arahata K, Engel AG (1986) Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 19(2):112–125. doi: 10.1002/ana.410190203 PubMedCrossRefGoogle Scholar
  3. Arahata K, Engel AG (1988) Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8 + cytotoxic and T8 + suppressor cells. Ann Neurol 23(5):493–499. doi: 10.1002/ana.410230511 PubMedCrossRefGoogle Scholar
  4. Argov Z, Taivassalo T, De Stefano N, Genge A, Karpati G, Arnold DL (1998) Intracellular phosphates in inclusion body myositis—a 31P magnetic resonance spectroscopy study. Muscle Nerve 21(11):1523–1525PubMedCrossRefGoogle Scholar
  5. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Howeler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR (2000) Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55(9):1385–1387CrossRefGoogle Scholar
  6. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, van Doorn PA, van Engelen BG, Hoogendijk JE, Howeler CJ, de Jager AE, Jennekens FG, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR (2002) Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51(3):369–372PubMedCrossRefGoogle Scholar
  7. Badrising UA, Maat-Schieman ML, van Houwelingen JC, van Doorn PA, van Duinen SG, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, Verschuuren JJ, Wintzen AR (2005) Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 252 (12):1448–1454. doi: 10.1007/s00415-005-0884-y Google Scholar
  8. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG, Dutch IBMSG (2004) Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63(12):2396–2398CrossRefGoogle Scholar
  9. Bartlett ML, Ginn L, Beitz L, Villalba ML, Plotz P, Bacharach SL (1999) Quantitative assessment of myositis in thigh muscles using magnetic resonance imaging. Magn Reson Imaging 17(2):183–191PubMedCrossRefGoogle Scholar
  10. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, Stojkovic T, Leite MI, Allenbach Y, Herson S, Brady S, Eymard B, Hilton-Jones D (2011) Long-term observational study of sporadic inclusion body myositis. Brain 134(Pt 11):3176–3184. doi: 10.1093/brain/awr213 PubMedCrossRefGoogle Scholar
  11. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). New Engl J Med 292(7):344–347. doi: 10.1056/NEJM197502132920706 CrossRefGoogle Scholar
  12. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56(4):255–286Google Scholar
  13. Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MF, Linssen WH, Wokke JH, de Visser M (2003) Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250(4):480–485. doi: 10.1007/s00415-003-1027-y PubMedCrossRefGoogle Scholar
  14. Cantwell C, Ryan M, O’Connell M, Cunningham P, Brennan D, Costigan D, Lynch T, Eustace S (2005) A comparison of inflammatory myopathies at whole-body turbo STIR MRI. Clin Radiol 60(2):261–267. doi: 10.1016/j.crad.2004.06.027 PubMedCrossRefGoogle Scholar
  15. Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, Styles P, Taylor DJ (2002) Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 125(Pt 7):1635–1645PubMedCrossRefGoogle Scholar
  16. Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70(6):418–424. doi: 10.1212/01.wnl.0000277527.69388.fe CrossRefGoogle Scholar
  17. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis and Rheumatism 62(9):2757–2766. doi: 10.1002/art.27572 PubMedCentralPubMedCrossRefGoogle Scholar
  18. Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, Brady S, Hilton-Jones D, Parton M, Hanna MG (2013) Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscular disorders: NMD. doi: 10.1016/j.nmd.2013.02.010
  19. Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA (2011a) Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology 50(6):1153–1161. doi: 10.1093/rheumatology/ker001 CrossRefGoogle Scholar
  20. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA (2011b) A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 134(Pt 11):3167–3175. doi: 10.1093/brain/awr217 PubMedCrossRefGoogle Scholar
  21. Dimachkie MM, Barohn RJ (2012) Idiopathic inflammatory myopathies. Semin Neurol 32(3):227–236. doi: 10.1055/s-0032-1329201 PubMedCentralPubMedCrossRefGoogle Scholar
  22. Dion E, Cherin P, Payan C, Fournet JC, Papo T, Maisonobe T, Auberton E, Chosidow O, Godeau P, Piette JC, Herson S, Grenier P (2002) Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 29(9):1897–1906PubMedGoogle Scholar
  23. Domire ZJ, McCullough MB, Chen Q, An KN (2009) Wave attenuation as a measure of muscle quality as measured by magnetic resonance elastography: initial results. J Biomech 42(4):537–540. doi: 10.1016/j.jbiomech.2008.11.034 PubMedCrossRefGoogle Scholar
  24. Ellis E, Ann Tan J, Lester S, Tucker G, Blumbergs P, Roberts-Thomson P, Limaye V (2012) Necrotizing myopathy: clinicoserologic associations. Muscle and Nerve 45(2):189–194. doi: 10.1002/mus.22279 PubMedCrossRefGoogle Scholar
  25. Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, Schleinitz N, Weiller PJ, Pouget J, Pellissier JF, Figarella-Branger D (2013) Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine 92(1):15–24. doi: 10.1097/MD.0b013e31827ebba1 PubMedCrossRefGoogle Scholar
  26. Fleckenstein JL (1996) Re: Cost-effectiveness of MR imaging in evaluating polymyositis. AJR. Am J Roentgenol 167(2):531–532. doi: 10.2214/ajr.167.2.8686645 PubMedCrossRefGoogle Scholar
  27. Fujino H, Kobayashi T, Goto I, Onitsuka H (1991) Magnetic resonance imaging of the muscles in patients with polymyositis and dermatomyositis. Muscle and Nerve 14(8):716–720. doi: 10.1002/mus.880140805 PubMedCrossRefGoogle Scholar
  28. Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle and Nerve 45(5):676–683. doi: 10.1002/mus.23302 PubMedCrossRefGoogle Scholar
  29. Gordon BA, Martinez S, Collins AJ (1995) Pyomyositis: characteristics at CT and MR imaging. Radiology 197(1):279–286Google Scholar
  30. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle and Nerve 41(2):185–190. doi: 10.1002/mus.21486 PubMedGoogle Scholar
  31. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscul Disord : NMD 14(5):337–345. 10–12 Oct 2003, Naarden. The Neth. doi: 10.1016/j.nmd.2004.02.006 CrossRefGoogle Scholar
  32. Hundt W, Stabler A, Reiser M (1999) MRI findings of muscle involvement in idiopathic hypereosinophilic syndrome. Eur Radiol 9(3):525–528PubMedCrossRefGoogle Scholar
  33. Jankharia BG, Chavhan GB, Krishnan P, Jankharia B (2005) MRI and ultrasound in solitary muscular and soft tissue cysticercosis. Skeletal Radiol 34(11):722–726. doi: 10.1007/s00256-005-0954-3 PubMedCrossRefGoogle Scholar
  34. Johnson RW, Williams FM, Kazi S, Dimachkie MM, Reveille JD (2003) Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis and Rheumatism 49(2):172–178. doi: 10.1002/art.11002 PubMedCrossRefGoogle Scholar
  35. Koffman BM, Rugiero M, Dalakas MC (1998) Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle and Nerve 21(1):115–117PubMedCrossRefGoogle Scholar
  36. Larue S, Maisonobe T, Benveniste O, Chapelon-Abric C, Lidove O, Papo T, Eymard B, Dubourg O (2011) Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg Psychiatry 82(6):674–677. doi: 10.1136/jnnp.2009.190751 CrossRefGoogle Scholar
  37. Layzer RB, Shearn MA, Satya-Murti S (1977) Eosinophilic polymyositis. Ann Neurol 1(1):65–71. doi: 10.1002/ana.410010106 CrossRefGoogle Scholar
  38. Le Roux K, Streichenberger N, Vial C, Petiot P, Feasson L, Bouhour F, Ninet J, Lachenal F, Broussolle C, Seve P (2007) Granulomatous myositis: a clinical study of thirteen cases. Muscle and Nerve 35(2):171–177. doi: 10.1002/mus.20683 PubMedCrossRefGoogle Scholar
  39. Liang C, Needham M (2011) Necrotizing autoimmune myopathy. Curr Opinion Rheumatol 23(6):612–619. doi: 10.1097/BOR.0b013e32834b324b CrossRefGoogle Scholar
  40. Lindberg C, Persson LI, Bjorkander J, Oldfors A (1994) Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurolog Scand 89(2):123–131CrossRefGoogle Scholar
  41. Lodi R, Taylor DJ, Tabrizi SJ, Hilton-Jones D, Squier MV, Seller A, Styles P, Schapira AH (1998) Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain 121(Pt 11):2119–2126PubMedCrossRefGoogle Scholar
  42. Lofberg M, Liewendahl K, Lamminen A, Korhola O, Somer H (1998) Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies. Arch Neurol 55(7):987–993PubMedCrossRefGoogle Scholar
  43. Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, Murray KJ (2004) Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 43(5):603–608. doi: 10.1093/rheumatology/keh130 CrossRefGoogle Scholar
  44. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheumatism 63(3):713–721. doi: 10.1002/art.30156 PubMedCentralPubMedCrossRefGoogle Scholar
  45. McCullough MB, Domire ZJ, Reed AM, Amin S, Ytterberg SR, Chen Q, An KN (2011) Evaluation of muscles affected by myositis using magnetic resonance elastography. Muscle and Nerve 43(4):585–590. doi: 10.1002/mus.21923 PubMedCentralPubMedCrossRefGoogle Scholar
  46. Middleton PJ, Alexander RM, Szymanski MT (1970) Severe myositis during recovery from influenza. Lancet 2(7672):533–535PubMedCrossRefGoogle Scholar
  47. Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73(4):420–428CrossRefGoogle Scholar
  48. Miller TT, Randolph DA Jr, Staron RB, Feldman F, Cushin S (1997) Fat-suppressed MRI of musculoskeletal infection: fast T2-weighted techniques versus gadolinium-enhanced T1-weighted images. Skeletal Radiol 26(11):654–658PubMedCrossRefGoogle Scholar
  49. Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, Mastaglia FL (2008) Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 79(9):1056–1060. doi: 10.1136/jnnp.2007.138891 CrossRefGoogle Scholar
  50. O’Connell MJ, Powell T, Brennan D, Lynch T, McCarthy CJ, Eustace SJ (2002) Whole-body MR imaging in the diagnosis of polymyositis. AJR. Am J Roentgenol 179(4):967–971. doi: 10.2214/ajr.179.4.1790967 PubMedCrossRefGoogle Scholar
  51. Owada T, Maezawa R, Kurasawa K, Okada H, Arai S, Fukuda T (2012) Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol 39(8):1659–1665. doi: 10.3899/jrheum.111597 PubMedCrossRefGoogle Scholar
  52. Park JH, Vansant JP, Kumar NG, Gibbs SJ, Curvin MS, Price RR, Partain CL, James AE Jr (1990) Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology 177(2):473–479Google Scholar
  53. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL (2001) Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle and Nerve 24(11):1526–1534PubMedCrossRefGoogle Scholar
  54. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, Verbeek MM, Badrising UA, Arnardottir S, Gheorghe K, Lundberg IE, Boelens WC, van Engelen BG, Pruijn GJ (2012) Autoantibodies to cytosolic 5’-nucleotidase IA in inclusion body myositis. Ann Neurol doi: 10.1002/ana.23822
  55. Qi J, Olsen NJ, Price RR, Winston JA, Park JH (2008) Diffusion-weighted imaging of inflammatory myopathies: polymyositis and dermatomyositis. J Magn Reson Imaging : JMRI 27(1):212–217. doi: 10.1002/jmri.21209 PubMedCrossRefGoogle Scholar
  56. Reimers CD, Schedel H, Fleckenstein JL, Nagele M, Witt TN, Pongratz DE, Vogl TJ (1994) Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 241(5):306–314PubMedCrossRefGoogle Scholar
  57. Restrepo CS, Lemos DF, Gordillo H, Odero R, Varghese T, Tiemann W, Rivas FF, Moncada R, Gimenez CR (2004) Imaging findings in musculoskeletal complications of AIDS. Radiograph A Rev Publ Radiol Soc North Am 24(4):1029–1049. doi: 10.1148/rg.244035151 CrossRefGoogle Scholar
  58. Rubin E, De la Rubia L, Pascual A, Dominguez J, Flores C (2010) Benign acute myositis associated with H1N1 influenza A virus infection. Eur J Pediatr 169(9):1159–1161. doi: 10.1007/s00431-010-1178-7 PubMedCrossRefGoogle Scholar
  59. Salajegheh M, Lam T, Greenberg SA (2011) Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS ONE 6(5):e20266. doi: 10.1371/journal.pone.0020266 PubMedCentralPubMedCrossRefGoogle Scholar
  60. Schedel H, Reimers CD, Nagele M, Witt TN, Pongratz DE, Vogl T (1992) Imaging techniques in myotonic dystrophy. A comparative study of ultrasound, computed tomography and magnetic resonance imaging of skeletal muscles. Eur J Radiol 15(3):230–238PubMedCrossRefGoogle Scholar
  61. Schedel H, Reimers CD, Vogl T, Witt TN (1995) Muscle edema in MR imaging of neuromuscular diseases. Acta Radiolog 36(3):228–232CrossRefGoogle Scholar
  62. Schulze M, Kotter I, Ernemann U, Fenchel M, Tzaribatchev N, Claussen CD, Horger M (2009) MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol 192(6):1708–1716. doi: 10.2214/AJR.08.1764 PubMedCrossRefGoogle Scholar
  63. Schweitzer ME, Fort J (1995) Cost-effectiveness of MR imaging in evaluating polymyositis. AJR Am J Roentgenol 165(6):1469–1471. doi: 10.2214/ajr.165.6.7484589 PubMedCrossRefGoogle Scholar
  64. Selva-O’Callaghan A, Grau JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, Andia-Navarro E, Vilardell-Tarres M (2010a) Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 123(6):558–562. doi: 10.1016/j.amjmed.2009.11.012 PubMedCrossRefGoogle Scholar
  65. Selva-O’Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M (2010b) Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 22(6):627–632. doi: 10.1097/BOR.0b013e32833f1075 PubMedCrossRefGoogle Scholar
  66. Smoyer-Tomic KE, Amato AA, Fernandes AW (2012) Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 13:103. doi: 10.1186/1471-2474-13-103 PubMedCentralPubMedCrossRefGoogle Scholar
  67. Soler R, Rodriguez E, Aguilera C, Fernandez R (2000) Magnetic resonance imaging of pyomyositis in 43 cases. Eur J Radiol 35(1):59–64PubMedCrossRefGoogle Scholar
  68. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ (2011) European federation of neurological S screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 18 (1):19-e13. doi: 10.1111/j.1468-1331.2010.03220.x Google Scholar
  69. Tomasova Studynkova J, Charvat F, Jarosova K, Vencovsky J (2007) The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 46(7):1174–1179. doi: 10.1093/rheumatology/kem088 CrossRefGoogle Scholar
  70. Tripathy SK, Sen RK, Akkina N, Hampannavar A, Tahasildar N, Limaye R (2012) Role of ultrasonography and magnetic resonance imaging in the diagnosis of intramuscular cysticercosis. Skeletal Radiol 41(9):1061–1066. doi: 10.1007/s00256-011-1320-2 PubMedCrossRefGoogle Scholar
  71. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M (2003) Polymyositis: an overdiagnosed entity. Neurology 61(3):316–321CrossRefGoogle Scholar
  72. van der Meulen MF, Hoogendijk JE, Wokke JH, de Visser M (2000) Oral pulsed high-dose dexamethasone for myositis. J Neurol 247(2):102–105PubMedCrossRefGoogle Scholar
  73. Weber MA, Jappe U, Essig M, Krix M, Ittrich C, Huttner HB, Meyding-Lamade U, Hartmann M, Kauczor HU, Delorme S (2006) Contrast-enhanced ultrasound in dermatomyositis- and polymyositis. J Neurol 253(12):1625–1632. doi: 10.1007/s00415-006-0318-5 PubMedCrossRefGoogle Scholar
  74. Yao L, Gai N (2012) Fat-corrected T2 measurement as a marker of active muscle disease in inflammatory myopathy. AJR. Am J Roentgenol 198(5):W475–W481. doi: 10.2214/AJR.11.7113 PubMedCrossRefGoogle Scholar
  75. Yoshida K, Kurosaka D, Joh K, Matsushima S, Takahashi E, Hirai K, Noda K, Ukichi T, Furuya K, Yanagimachi M, Kingetsu I, Fukuda K, Yamada A (2010) Fasciitis as a common lesion of dermatomyositis, demonstrated early after disease onset by en bloc biopsy combined with magnetic resonance imaging. Arthritis Rheumatism 62(12):3751–3759. doi: 10.1002/art.27704 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Umesh A. Badrising
    • 1
  • Hermien E. Kan
    • 1
  • Jan JGM Verschuuren
    • 1
  1. 1.Department of Neurology, K5-QLeiden University Medical CentreLeidenThe Netherlands

Personalised recommendations